Allegro Ophthalmics Expands Its Anti-Integrin Portfolio with New Front-of-the-Eye Drug Candidate ALG-1007 for the Treatment of Dry Eye Disease

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ASCRS?src=hash" target="_blank"gt;#ASCRSlt;/agt;--Allegro Ophthalmics expands anti-integrin portfolio with new drug candidate ALG-1007 for dry eye disease, forms new Cornea Scientific Advisory Board.

Full Story →